8-K: Gossamer Bio Reports Q3 2025 Results, PROSERA Data Feb 2026

Gossamer Bio announced its third quarter 2025 financial results, highlighted by $180.2 million in cash and an expected February 2026 readout for the PROSERA Phase 3 study.

Summary

• Reported a net loss of $48.2 million, or $0.21 basic net loss per share, for the quarter ended September 30, 2025, compared to a net loss of $30.8 million, or $0.14 basic net loss per share, for the same period in 2024.
• Cash, cash equivalents, and marketable securities totaled $180.2 million as of September 30, 2025, down from $294.5 million at December 31, 2024.
• Current cash, cash equivalents, and marketable securities are expected to fund operating and capital expenditures into 2027.
• Topline results from the Phase 3 PROSERA Study for seralutinib in pulmonary arterial hypertension (PAH) are expected in February 2026.
• The first clinical site was activated for the global, registrational Phase 3 SERANATA Study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) patients.
• Entered into a strategic option agreement to acquire Respira Therapeutics Inc. and its lead product candidate, an inhaled formulation of vardenafil, for 1.5 million shares of Gossamer Bio common stock if the option is exercised.

Sentiment

Score: 5

Explanation: The filing presents a mixed bag. Positive clinical progress with two Phase 3 studies and a strategic acquisition option are offset by increasing net losses and R&D expenses, and a significant reduction in cash reserves, despite the extended cash runway into 2027. The financial performance is concerning, but clinical milestones offer future potential.

Positives

• Completed enrollment for the Phase 3 PROSERA Study with 390 WHO Functional Class II and III PAH patients.
• Activated the first clinical site for the global, registrational Phase 3 SERANATA Study in PH-ILD patients.
• Presented one oral and four poster presentations related to seralutinib at the European Respiratory Society (ERS) Congress 2025, highlighting its potential mechanisms and effects.
• Entered a strategic option agreement to acquire Respira Therapeutics Inc. for an inhaled vardenafil product, designed to minimize near-term cash burn and preserve financial position.
• Current cash, cash equivalents, and marketable securities of $180.2 million are expected to fund operating and capital expenditures into 2027.

Negatives

• Net loss for the quarter ended September 30, 2025, increased to $48.2 million from $30.8 million for the same period in 2024.
• Research and Development (R&D) expenses increased to $45.5 million for Q3 2025, up from $34.9 million for Q3 2024.
• General and Administrative (G&A) expenses increased to $9.4 million for Q3 2025, up from $8.5 million for Q3 2024.
• Cash, cash equivalents, and marketable securities decreased by $114.3 million from $294.5 million at December 31, 2024, to $180.2 million at September 30, 2025.
• Accumulated deficit increased to $(1,391,700) thousand as of September 30, 2025, from $(1,268,568) thousand at December 31, 2024.

Risks

• Potential delays in the commencement, enrollment, and completion of clinical trials.
• Disruption to operations from unexpected events, including clinical trial delays.
• Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
• Results of preclinical studies and early clinical trials with seralutinib are not necessarily predictive of future results.
• The success of clinical trials and preclinical studies for seralutinib is uncertain.
• Regulatory developments in the United States and foreign countries may impact product approval.
• Unexpected adverse side effects or inadequate efficacy of seralutinib may limit its development, regulatory approval, and/or commercialization, or may result in clinical holds, recalls, or product liability claims.
• Ability to obtain and maintain intellectual property protection for seralutinib.
• Ability to comply with obligations in collaboration agreements with third parties or licensing agreements.
• Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may adversely affect business and financial condition.
• Capital resources may be used sooner than expected.

Future Outlook

Gossamer Bio anticipates topline results from its Phase 3 PROSERA Study in February 2026. The company expects its current cash, cash equivalents, and marketable securities to fund operations into 2027. If the option to acquire Respira Therapeutics Inc. is exercised, further clinical trials for inhaled vardenafil are not expected to commence until at least 2027.

Management Comments

• "We are proud to be progressing through the final stages of the PROSERA Phase 3 Study. This is a pivotal moment for our team, and I am continually impressed by the focus, diligence, and professionalism that everyone brings to this important work. We look forward to sharing top-line results with the community in February of next year." Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio.
• "At the same time, we are encouraged by the engagement from the PH-ILD community as we begin to activate the first clinical sites in the SERANATA Phase 3 study. We are grateful for the opportunity to collaborate closely with physicians and patients to better understand the challenges for those living with this challenging and under-treated disease. We are excited to begin enrollment, and we are hopeful that our collective efforts will ultimately improve the lives of patients living with PH-ILD." Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio.

Industry Context

Gossamer Bio operates in the highly specialized and competitive biopharmaceutical sector, focusing on pulmonary hypertension, a market with significant unmet medical needs. The development of seralutinib for PAH and PH-ILD, alongside the strategic option for inhaled vardenafil, positions the company to address these complex and under-treated diseases. The collaboration with Chiesi Group leverages broader industry expertise and resources for development and potential commercialization, which is a common strategy in the biopharma industry to de-risk and accelerate drug development.

Stakeholder Impact

• Shareholders face potential dilution if the Respira option is exercised (less than 1% of outstanding shares), and continued financial losses may impact share value, though positive clinical trial results could significantly boost it.
• Patients with PAH and PH-ILD could benefit from the successful development and commercialization of seralutinib and inhaled vardenafil, offering new treatment options for under-treated diseases.
• Employees are engaged in critical late-stage clinical development, with potential for growth if pipeline candidates succeed.
• The collaboration with Chiesi Group continues, impacting both companies' development and commercialization strategies for seralutinib.

Next Steps

• Announce topline results from the Phase 3 PROSERA Study in February 2026.
• Continue activating clinical sites and enrolling patients for the Phase 3 SERANATA Study in PH-ILD.
• Evaluate and potentially exercise the option to acquire Respira Therapeutics Inc.
• If the Respira option is exercised, commence further clinical trials for inhaled vardenafil no earlier than 2027.

Key Dates

Recommendation

While Gossamer Bio is making significant clinical progress with seralutinib, including an upcoming Phase 3 readout and the initiation of another registrational study, the financial results show increasing losses and a substantial reduction in cash reserves. The strategic option to acquire Respira adds a new pipeline candidate with minimal near-term cash impact, but further clinical trials for it are years away. The company's cash runway into 2027 provides some stability, but the increased burn rate and the inherent risks of late-stage clinical development warrant a 'hold' position until the PROSERA Phase 3 results are announced, which will be a critical determinant of future valuation.

Keywords

Gossamer Bio, GOSS, Seralutinib, Pulmonary Arterial Hypertension, PAH, Pulmonary Hypertension Interstitial Lung Disease, PH-ILD, PROSERA, SERANATA, Clinical Trial, Phase 3, Biopharmaceutical, Respira Therapeutics, Vardenafil, Q3 2025 Earnings, Financial Results